How Long Does BCG Treatment for Bladder Cancer Last?

BCG treatment for bladder cancer typically lasts between one and three years, depending on the protocol your urologist follows and how well you tolerate the therapy. The treatment unfolds in two distinct phases: a short induction course of about six weeks, followed by a much longer maintenance phase that can stretch up to three years. That said, the gap between what guidelines recommend and what patients actually complete is enormous, and understanding why helps you plan for what lies ahead.

What a Standard BCG Schedule Looks Like

BCG therapy begins after a procedure called transurethral resection, where the surgeon removes visible tumor from the bladder wall. A few weeks later, the induction phase starts: once-weekly instillations of live BCG bacteria directly into the bladder through a catheter, typically for six consecutive weeks. Each session involves holding the solution in your bladder for about two hours before urinating it out. After those initial six weeks, you undergo a cystoscopy and other tests to see how the bladder has responded.

Maintenance is where the real variation appears. The most widely referenced protocol calls for three weekly instillations given at months 3 and 6 after induction, then every six months out to three years, totaling up to 27 individual treatments over the full course. Other centers use different schedules. One approach uses monthly instillations for 12 months after induction.¹ Another uses three weekly treatments every three to six months for roughly two years total.² The common thread across all of them: induction plus maintenance together is the standard of care for high-risk disease.³

Why Maintenance Changes the Outcome

A reasonable question is whether the maintenance phase is worth the hassle, given how long it drags on. The evidence strongly says yes for high-risk patients. A comparative study found that patients who received adequate BCG (defined as completing most of induction plus at least a couple of maintenance cycles) had a five-year recurrence-free survival of about 72%, compared to roughly 52% for those who received inadequate treatment. Overall survival at five years was also substantially better: around 88% versus 71%.⁴ A systematic review of real-world data echoed this, showing that two-year and five-year recurrence-free survival were numerically longer with maintenance compared to induction alone.⁵

For patients with lower-risk tumors, the calculus can differ. Induction alone has shown reasonable results in some settings, with three-year disease-free survival around 66% and progression-free survival near 87% in one retrospective study of high-risk patients who received only the six-week course.⁶ But for truly high-risk disease, skipping maintenance means accepting a meaningfully higher chance of the cancer coming back.

One Year Versus Three Years of Maintenance

Even among patients who do get maintenance, the question of how long is hotly debated. A study from China directly compared one-year and three-year maintenance regimens and found the three-year course provided substantially better protection against recurrence. In their analysis, the three-year group had a recurrence hazard less than a third that of the one-year group, and this advantage held even in the highest-risk patients.⁷

This doesn’t mean every patient must endure three full years. Guidelines generally recommend the longer course for high-risk tumors and allow shorter courses for intermediate-risk disease. Your urologist will weigh tumor grade, stage, size, and whether carcinoma in situ is present when deciding how long to continue. The trade-off is always between better cancer control and the cumulative burden of side effects over months and years of treatment.

Side Effects and Why So Many People Stop Early

BCG side effects are not subtle. Bladder irritation, a general flu-like feeling, and fever are extremely common. Around 60% of patients experience side effects of some kind, with roughly one in ten developing more serious toxicity.⁸ About 8% of patients have to stop treatment altogether because of complications.⁹

The side effects tend to accumulate over time, which is one reason real-world completion rates are so dismal. Burning during urination, urgency, frequency, and fatigue after each instillation can be manageable for six weeks but become exhausting when you’re facing them every few months for years. Rarer but more serious complications include BCG infection spreading beyond the bladder, joint pain, and allergic reactions. Most urologists pre-treat with anti-inflammatory medications and recommend increasing fluid intake on treatment days, but there’s no getting around the fact that BCG is a live bacterial product being placed directly in your bladder, and your immune system is supposed to react.

Real-World Completion Rates Are Strikingly Low

Here is perhaps the most important practical fact about BCG duration: most people do not finish the recommended course. A systematic review found that only about 28% of patients completed at least one year of maintenance.⁵ Across eight studies examining adequate treatment, about 60% of patients did not receive what would be considered an adequate BCG course, meaning they missed too many instillations during induction, maintenance, or both.

The numbers for three-year protocols are even starker. One review reported a 90% withdrawal rate from the full three-year course, with only about 10% of patients making it all the way through. Nearly half stopped within the first year. The reasons vary: side effects, BCG supply issues, personal burden, and sometimes disease recurrence that changes the treatment plan entirely. This reality means that “how long does BCG last” has two answers. The recommended duration is one to three years. The duration most people actually experience is considerably shorter.

BCG Shortages and Reduced-Dose Regimens

A complicating factor over the past decade has been a global shortage of BCG for bladder cancer. Only a handful of manufacturers produce BCG strains approved for intravesical use, and production disruptions have forced urologists to ration doses. This has led to widespread use of reduced-dose regimens, typically one-third of the standard dose.

The encouraging news is that reduced doses appear to work reasonably well. A large retrospective study from a tertiary cancer center compared one-third dose to full dose in over 500 patients and found no significant difference in time to recurrence, time to progression, or cancer-specific survival. The five-year cancer-specific survival rate was about 98.5% for the reduced-dose group and 95.7% for the full-dose group, a gap that was not statistically meaningful.¹⁰ A systematic review and meta-analysis reached a similar conclusion, suggesting that reduced-dose regimens could reasonably be offered during shortage periods.¹¹ Interestingly, patients receiving reduced doses were less likely to stop treatment due to toxicity, which could translate into better completion of the full maintenance schedule.¹²

Whether reduced doses remain standard after shortages resolve is an open question. Some researchers suspect the lower side-effect burden might actually improve long-term outcomes by keeping patients on maintenance longer, but no randomized trial has tested this head-to-head in a definitive way.

How BCG Works in the Bladder

BCG is a live but weakened strain of the bacterium that causes tuberculosis in cattle. When placed in the bladder, it attaches to the bladder wall and provokes a strong local immune response. The bacteria activate both the fast-acting innate immune system and the more targeted adaptive immune system, eventually leading to destruction of residual tumor cells.¹³ This is why BCG is considered one of the earliest and most successful forms of cancer immunotherapy, with roots going back more than four decades in clinical practice.¹⁴

Recent research has uncovered something unexpected: BCG administered in the bladder doesn’t just stay local. In both mice and humans, BCG colonizes the bone marrow and reprograms the stem cells that produce immune cells. This reprogramming amplifies the production of neutrophils, monocytes, and dendritic cells that then remodel the tumor environment and drive broader anti-tumor immunity.¹⁵ This systemic effect may help explain why repeated instillations over months or years matter: each round of BCG may reinforce and sustain these immune changes beyond the bladder itself.

When BCG Fails

Up to 40% of patients will ultimately fail BCG therapy, meaning the cancer comes back despite treatment. Clinicians classify failures into specific categories that determine what happens next. If a tumor reappears within six months of completing adequate BCG (or carcinoma in situ reappears within twelve months), the disease is considered “BCG-unresponsive,” a label that carries important treatment implications.¹⁶

For BCG-unresponsive disease, one widely studied salvage regimen combines intravesical gemcitabine and docetaxel. Long-term follow-up data show a complete response rate of about 74% at three months, with the median duration of that response lasting roughly two years.¹⁷ Newer approaches are also emerging. An IL-15 receptor agonist combined with BCG showed a 71% complete response rate in BCG-unresponsive patients, with responders maintaining their bladder at rates above 90% at two years and around 84% at three years.¹⁸

The alternative, and the traditional recommendation for BCG-unresponsive disease, is radical cystectomy, the complete surgical removal of the bladder. The newer intravesical salvage options exist precisely because many patients want to avoid that surgery if there is a reasonable alternative.

Surveillance After Treatment Ends

Whether you complete the full three-year course or stop earlier, the monitoring phase extends well beyond the last instillation. Cystoscopy, where a camera is passed into the bladder to look for recurrence, is the backbone of surveillance. Most guidelines recommend the first follow-up cystoscopy about three months after the initial tumor resection. A large analysis of over 26,000 patients found that the two-to-four-month window offered the best outcomes, with delays beyond eight months associated with substantially higher risks of progression and cancer-specific death.¹⁹

After the initial check, cystoscopies continue at regular intervals, usually every three to six months for the first two years, then annually for several more years. For high-risk disease, surveillance may continue indefinitely. Urine tests and imaging studies supplement the cystoscopies. The duration of surveillance, then, often outlasts the treatment itself, and this long tail of monitoring visits is something to plan for when thinking about the total time commitment of a bladder cancer diagnosis.

Combining BCG With Immune Checkpoint Drugs

One of the most active areas of research involves pairing BCG with immune checkpoint inhibitors, the drugs that have transformed treatment for advanced bladder cancer and many other cancers. The biological logic is sound: BCG primes the immune system against the tumor, but it also recruits regulatory immune cells that can dampen the attack. Checkpoint inhibitors could theoretically release those brakes and let BCG work more effectively.²⁰

The clinical reality has been more humbling. A recent review of the evidence noted that while the immunological rationale for the combination is strong, phase III trials have so far failed to show that adding a checkpoint inhibitor upfront to BCG improves cancer outcomes compared to BCG alone.²¹ One such phase III trial, CREST, tested the PD-1 inhibitor sasanlimab alongside BCG in treatment-naive patients and did not meet its primary endpoint.³ These combinations may yet find their place, perhaps in BCG-experienced or BCG-failing patients rather than as first-line additions, but the idea that simply layering on a checkpoint inhibitor will shorten or improve BCG treatment hasn’t panned out so far.²²

Can Biomarkers Predict Who Needs the Full Course?

One of the frustrations of BCG therapy is that it is essentially one-size-fits-all. Every high-risk patient gets the same schedule, even though some tumors will respond completely after induction while others will prove resistant from the start. A lot of research is focused on finding biomarkers that could sort patients early, telling clinicians who truly needs three years of maintenance and who might safely stop sooner.

Urinary cytokine panels, which measure the immune chemicals shed into urine during BCG instillations, have shown promise. One panel based on nine cytokines measured across the induction course predicted recurrence with strong accuracy.²³ A systematic review confirmed that broader biomarker panels, including urinary cytokines and fluorescent in-situ hybridization patterns from urine cytology, showed the most robust correlation with treatment response.²⁴ Tissue-level markers are also under investigation: elevated expression of certain proteins in tumor samples has been linked to BCG resistance and reduced immune cell infiltration in the tumor.²⁵

None of these markers have entered routine clinical use yet. The field is still at the stage of validating promising candidates in larger, independent patient groups. But the eventual goal is clear: personalize BCG duration so that patients who need aggressive, prolonged treatment get it, while those whose tumors are already eradicated can be spared years of instillations they didn’t need.

Does the BCG Strain Matter for Duration?

BCG is not a single product. There are about a dozen strains in use worldwide, descendants of the original bacterium that have diverged genetically over a century of laboratory passage. Patients sometimes wonder whether the strain they receive affects how long treatment should last or how well it works. A large meta-analysis covering more than 15,000 patients across ten different strains found that while some strains showed slightly different short-term recurrence rates, no single strain was significantly better than another at preventing recurrence in the long run.²⁶ The safety profiles also appear broadly consistent across strains.²⁷ In practical terms, this means the strain you receive, often determined by what your hospital can source, is unlikely to change how long your treatment lasts or how effective it will be.